Search research articles
Contact Us
Filters
Showing results (371-380 of 382) with videos related to
Page
of 39
Sort By:
Mucosal Immunology
|
January 28, 2016
IL-36α expression is elevated in ulcerative colitis and promotes colonic inflammation
S E Russell, R M Horan, A M Stefanska, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
July 23, 2022
Identification of fusions with potential clinical significance in melanoma
Jakob M T Moran, Long P Le, Valentina Nardi, et al.
British Journal of Pharmacology
|
May 31, 2016
Effect of flecainide derivatives on sarcoplasmic reticulum calcium release suggests a lack of direct action on the cardiac ryanodine receptor
Mark L Bannister, Anita Alvarez-Laviada, N Lowri Thomas, et al.
The Annals of Thoracic Surgery
|
January 5, 2013
Midterm results of David reimplantation in patients with connective tissue disorder
Lars G Svensson, Eugene H Blackstone, Mazin Alsalihi, et al.
Immunity
|
March 6, 2016
The Vaccine Adjuvant Chitosan Promotes Cellular Immunity via DNA Sensor cGAS-STING-Dependent Induction of Type I Interferons
Elizabeth C Carroll, Lei Jin, Andres Mori, et al.
Nature
|
June 1, 2001
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
Y Ogura, D K Bonen, N Inohara, et al.
American Journal of Medical Genetics. Part A
|
May 7, 2011
Distinctive phenotype in 9 patients with deletion of chromosome 1q24-q25
Deepika D'Cunha Burkardt, Jill A Rosenfeld, Maria L Helgeson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 27, 2005
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients
H Cortes-Funes, C Gomez, R Rosell, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 10, 2001
Design and synthesis of irreversible depsipeptidyl human rhinovirus 3C protease inhibitors
S E Webber, J T Marakovits, P S Dragovich, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 1, 2025
A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial
R A Soo, K Vervita, M Früh, et al.
Page
of 39
Search research articles
Search
Showing results (371-380 of 382) with videos related to
Sort By:
Page
of 39
Mucosal Immunology
|
January 28, 2016
IL-36α expression is elevated in ulcerative colitis and promotes colonic inflammation
S E Russell, R M Horan, A M Stefanska, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
July 23, 2022
Identification of fusions with potential clinical significance in melanoma
Jakob M T Moran, Long P Le, Valentina Nardi, et al.
British Journal of Pharmacology
|
May 31, 2016
Effect of flecainide derivatives on sarcoplasmic reticulum calcium release suggests a lack of direct action on the cardiac ryanodine receptor
Mark L Bannister, Anita Alvarez-Laviada, N Lowri Thomas, et al.
The Annals of Thoracic Surgery
|
January 5, 2013
Midterm results of David reimplantation in patients with connective tissue disorder
Lars G Svensson, Eugene H Blackstone, Mazin Alsalihi, et al.
Immunity
|
March 6, 2016
The Vaccine Adjuvant Chitosan Promotes Cellular Immunity via DNA Sensor cGAS-STING-Dependent Induction of Type I Interferons
Elizabeth C Carroll, Lei Jin, Andres Mori, et al.
Nature
|
June 1, 2001
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
Y Ogura, D K Bonen, N Inohara, et al.
American Journal of Medical Genetics. Part A
|
May 7, 2011
Distinctive phenotype in 9 patients with deletion of chromosome 1q24-q25
Deepika D'Cunha Burkardt, Jill A Rosenfeld, Maria L Helgeson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 27, 2005
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients
H Cortes-Funes, C Gomez, R Rosell, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 10, 2001
Design and synthesis of irreversible depsipeptidyl human rhinovirus 3C protease inhibitors
S E Webber, J T Marakovits, P S Dragovich, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 1, 2025
A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial
R A Soo, K Vervita, M Früh, et al.
Page
of 39